Efficacy and safety of tezepelumab in participants with severe chronic rhinosinusitis with nasal polyposis - WAYPOINT

Study identifier:D5242C00001

ClinicalTrials.gov identifier:NCT04851964

EudraCT identifier:2020-003062-39

CTIS identifier:N/A

Recruitment Complete

Official Title

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis (WAYPOINT)

Medical condition

Chronic rhinosinusitis with nasal polyps

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

416

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 22 Apr 2021
Estimated Primary Completion Date: 04 Oct 2024
Estimated Study Completion Date: 18 Dec 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Amgen

Inclusion and exclusion criteria